Clinical and experimental studies have also suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2-Is; Tsai et al., 2021) and incretin-based drugs, including glucagon-like peptide-1 receptor agonists (GLP1-RAs) and dipeptidyl peptidase-4 inhibitors (DPP4-Is; Darsalia et al., 2015), may decrease the risk of stroke. Here, DPP4 is linked to stroke disorder.